CHATHAM, N.J. — Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) , a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional safety and tolerability data from RESILIENT, the second positive Phase 3 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of...
Latest News
Chatham, N.J. — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral presentation on March 23, 2023, at the Rare Disease Innovation and Partnership Summit being held as a hybrid event in...
Chatham, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present an oral presentation and poster at the 5th International Congress on Controversies in Fibromyalgia being...
RESEARCH TRIANGLE PARK, N.C. – Worldwide Clinical Trials, Inc., (Worldwide) the industry’s leading global, midsized, full-service contract research organization (CRO), announced researchers Anna Gres, Ph.D. and Matthew Confeld, Ph.D., Pharm.D., have been selected for the esteemed Michael F. Murphy Clinical Research Methodology Fellowship Program. Established in 2017, the competitive two-year program...
Ionis completed a Phase 2 clinical study evaluating cimdelirsen (IONIS-GHR-LRx) as an addon therapy in patients with uncontrolled acromegaly despite stable therapy with long-acting somatostatin receptor ligands (SRL). Based on the results of this Phase 2 study and a preliminary analysis of the ongoing open-label study, proof of mechanism was...
Compared with chemotherapy conditioning, total body irradiation (TBI) may lead to better outcomes prior to allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL), according to research in the Journal of Clinical Oncology. Patients with ALL commonly receive TBI and etoposide before undergoing HSCT; however there...
At night, after Tammy Hruskach tucks her boys in bed, she prays a mother’s prayer for constant protection and guidance — first for Logan, 9; and then for her 7-year-old, Austin. “And God,” she always adds as she brushes the bangs off Austin’s forehead, her hand lingering in one last...
BOSTON, Mass. — Therapeutic cancer vaccines are a form of immunotherapy in the making that could not only destroy cancer cells in patients, but keep a cancer from coming back and spreading. Multiple therapeutic cancer vaccines are being studied in clinical trials, but despite their promise, they are not routinely...
IBEC researchers led by Javier Ramón and Juan M. Fernández develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model...
Over 100,000 people suffer from multiple sclerosis in Germany alone. Despite intensive research, the factors that trigger the disease and influence its progress remain unclear. Scientists from the Max Planck Institute of Neurobiology in Martinsried and an international research team have succeeded in attaining three important new insights into the...